<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aldesleukin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aldesleukin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aldesleukin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11039" href="/d/html/11039.html" rel="external">see "Aldesleukin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13299" href="/d/html/13299.html" rel="external">see "Aldesleukin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708605"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Capillary leak syndrome:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Capillary leak syndrome, including life-threatening or fatal reactions, has occurred in patients treated with aldesleukin. Do not administer aldesleukin to patients with significant cardiac, pulmonary, renal, and hepatic impairment. Administer aldesleukin in a hospital setting with an intensive care facility. Withhold or discontinue aldesleukin as recommended.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neurologic toxicity, which may be life-threatening or result in coma or permanent neurological deficits, has occurred in patients treated with aldesleukin. Withhold or discontinue aldesleukin as recommended.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infections:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious infections including sepsis and bacterial endocarditis have occurred in patients treated with aldesleukin. Treat preexisting bacterial infections prior to initiation of aldesleukin therapy and withhold aldesleukin as recommended.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F12806506"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Proleukin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865587"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Proleukin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F131288"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Biological Response Modulator;</li>
<li>
                        Antineoplastic Agent, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F131255"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">Do not administer aldesleukin in patients with significant cardiac, pulmonary, kidney, or hepatic impairment. Evaluate and treat CNS metastases prior to aldesleukin treatment initiation; avoid use in patients with seizure disorder or abnormal CNS imaging. Treat preexisting bacterial infections prior to aldesleukin treatment initiation. Serum creatinine should be &lt;1.5 mg/dL prior to aldesleukin treatment initiation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Premedication:</i> Premedicate patients with an antipyretic immediately prior to treatment initiation and continue as needed to reduce fever. Aldesleukin doses &gt;12 to 15 million units/m<sup>2</sup> are associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10561265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10561265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Prophylaxis:</i> Consider antibiotic prophylaxis (per institutional guidance) prior to and during treatment with aldesleukin in patients with indwelling central lines. Administer GI prophylaxis (for GI irritation/bleeding) during treatment with aldesleukin.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd9cc34e-82d0-44d6-b7ae-298070c37e0c">Melanoma, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, metastatic:</b>
<b>IV:</b> 600,000 units/kg every 8 hours for a maximum of 14 doses (days 1 to 5); after 9 days off have elapsed (days 6 to 14), repeat with a second cycle (on days 15 to 19) for a maximum of 28 doses per course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10561265','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10561265','lexi-content-ref-Manu.1'])">Ref</a></span>); evaluate for response ~4 weeks after completion of course and again immediately prior to next treatment cycle; additional courses may be administered at least 7 weeks after hospital discharge date, if treatment response observed without adverse events leading to treatment discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i> 720,000 units/kg every 8 hours for 14 doses; repeat cycle after a 6- to 9-day rest period. Additional courses of treatment were administered if tumor regression occurred or for stable disease (up to maximum of 5 treatment courses); each course of therapy was typically separated by a 6- to 12-week interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10561265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10561265'])">Ref</a></span>) <b>or </b>720,000 units/kg every 8 hours for 12 to 15 doses; repeat with a second cycle ~14 days after the first dose of the initial cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18765555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18765555'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b715480b-2aac-4a06-9d86-f745e8c76541">Renal cell carcinoma, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, metastatic: Note: </b>May be an option in patients with progression following treatment with PD-1/PD-L1 inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30777131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30777131'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 600,000 units/kg every 8 hours for a maximum of 14 doses (days 1 to 5); after 9 days off have elapsed (days 6 to 14), repeat with a second cycle (on days 15 to 19) for a maximum of 28 doses per course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15625368','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15625368','lexi-content-ref-Manu.1'])">Ref</a></span>); evaluate for response ~4 weeks after completion of course and again immediately prior to next treatment cycle; additional courses may be administered at least 7 weeks after hospital discharge date, if treatment response observed without adverse events leading to treatment discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV: </b>720,000 units/kg every 8 hours for up to 12 doses; then after 10 to 15 days have elapsed, repeat with a second cycle for a total of 24 doses per course; may repeat course if tumor regression observed or stable disease (and if no contraindications) at least 2 months after hospital discharge date (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18457330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18457330'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991864"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Serum creatinine ≤1.5 mg/dL: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum creatinine &gt;1.5 mg/dL: Do not initiate aldesleukin; treatment is contraindicated in significant kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute kidney toxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Serum creatinine &gt;4.5 mg/dL (or ≥4 mg/dL with severe volume overload, acidosis, or hyperkalemia): Withhold aldesleukin; may resume when serum creatinine &lt;1.5 mg/dL or baseline and with stable fluid and electrolyte status.</p>
<p style="text-indent:-2em;margin-left:4em;">Persistent oliguria or urine output &lt;10 mL/hour for 16 to 24 hours with rising serum creatinine: Withhold aldesleukin; may resume when urine output is &gt;10 mL/hour with serum creatinine decrease of &gt;1.5 mg/dL or normalization.</p>
<p style="text-indent:-2em;margin-left:4em;">Kidney failure requiring hemodialysis for &gt;72 hours: Permanently discontinue aldesleukin.</p></div>
<div class="block doha drugH1Div" id="F50989163"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation: </b>There are no dosage adjustments provided in the manufacturer's labeling; however, aldesleukin is contraindicated in significant hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute hepatotoxicity during treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Liver pain or ≥ grade 3 AST or ALT elevation: Withhold aldesleukin and discontinue balance of cycle; may initiate a new course of treatment (if indicated) no sooner than 7 weeks following resolution of signs of hepatic toxicity and hospital discharge.</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic failure: Permanently discontinue aldesleukin.</p></div>
<div class="block doo drugH1Div" id="F57462326"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> The dosing in the FDA-approved prescribing information should be followed in all patients, regardless of obesity status. If a patient with a BMI ≥30 kg/m<sup>2</sup> experiences high-grade toxicity from systemic anticancer therapy, the same dosage modification recommendations should be followed for all patients, regardless of obesity status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F9647545"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Withhold or interrupt a dose, or permanently discontinue aldesleukin for toxicity; do not reduce the dose.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Aldesleukin Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">Adverse reaction</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Severity</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Aldesleukin dosage modification</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> CLS = capillary leak syndrome; FIT = fecal immunochemical test; FOBT = fecal occult blood test.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Cardiovascular toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Atrial fibrillation, supraventricular tachycardia, bradycardia (requiring treatment, or is recurrent or persistent)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold aldesleukin until patient is asymptomatic with full recovery to normal sinus rhythm.</p>
<p style="text-indent:0em;text-align:left;">Initiate standard management for CLS<sup>a</sup>, including intensive care, as necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Decrease in systolic BP to &lt;90 mm Hg (with increasing requirements for pressors)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold aldesleukin; may resume when systolic BP ≥90 mm Hg and stable or pressor requirements improve.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Sustained ventricular tachycardia (≥5 beats), cardiac rhythm disturbances not controlled or unresponsive to treatment, ECG changes consistent with myocardial infarction, ischemia, angina/chest pain, or cardiac tamponade</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue aldesleukin.</p>
<p style="text-indent:0em;text-align:left;">Initiate standard management for CLS, including intensive care, as necessary.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">CNS toxicity</p></td>
<td align="left">
<p style="text-indent:0em;">Mental status changes, including moderate confusion, moderate to severe lethargy or somnolence, or agitation</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold aldesleukin until complete resolution.</p>
<p style="text-indent:0em;">Initiate standard management for CLS, including intensive care, as necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Coma or toxic psychosis lasting &gt;48 hours, seizures (repetitive or difficult to control)</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue aldesleukin.</p>
<p style="text-indent:0em;">Initiate standard management for CLS, including intensive care, as necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Dermatologic toxicity</p></td>
<td align="left">
<p style="text-indent:0em;">Bullous dermatitis or marked worsening of preexisting skin condition</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold aldesleukin until resolution of all signs of bullous dermatitis.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">GI toxicity</p></td>
<td align="left">
<p style="text-indent:0em;">FIT<sup>a</sup> or FOBT<sup>a</sup> positive</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold aldesleukin until FIT or FOBT negative.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Bowel ischemia/perforation or GI bleeding (requiring surgery)</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue aldesleukin.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hyperglycemia and/or diabetes mellitus</p></td>
<td align="left">
<p style="text-indent:0em;">Any (clinically significant)</p></td>
<td align="left">
<p style="text-indent:0em;">Initiate treatment with insulin as clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hypersensitivity reaction</p></td>
<td align="left">
<p style="text-indent:0em;">Severe</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue aldesleukin.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Hypothyroidism</p></td>
<td align="left">
<p style="text-indent:0em;">Any (clinically significant)</p></td>
<td align="left">
<p style="text-indent:0em;">Initiate thyroid replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Infection</p></td>
<td align="left">
<p style="text-indent:0em;">Sepsis, hemodynamic instability</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold aldesleukin until resolution of sepsis syndrome, infection is being treated, and patient is clinically stable.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Infusion-related reaction</p></td>
<td align="left">
<p style="text-indent:0em;">Any (clinically significant)</p></td>
<td align="left">
<p style="text-indent:0em;">Continue antipyretic therapy during treatment as needed for fever.</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;">Respiratory toxicity</p></td>
<td align="left">
<p style="text-indent:0em;">Oxygen saturation &lt;90%</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold aldesleukin until oxygen saturation is &gt;90%.</p>
<p style="text-indent:0em;">Initiate standard management for CLS, including intensive care, as necessary.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Intubation for &gt;72 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Permanently discontinue aldesleukin.</p>
<p style="text-indent:0em;">Initiate standard management for CLS, including intensive care, as necessary.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F131256"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F9647544"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13299" href="/d/html/13299.html" rel="external">see "Aldesleukin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Dosing and frequency may vary by indication, protocol, and/or treatment phase and hematologic response; refer to specific protocols. Consider premedication with an antipyretic to reduce fever, an H<sub>2</sub> antagonist for prophylaxis of gastrointestinal irritation/bleeding, antiemetics, and antidiarrheals; continue for 12 hours after the last aldesleukin dose. Antibiotic prophylaxis is recommended to reduce the incidence of infection. Recommendations for antiemetics use may vary: Aldesleukin doses &gt;12 to 15 million units/m<sup>2</sup> are associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637'])">Ref</a></span>); however, aldesleukin is not included in the most updated pediatric classification of acute emetogenicity clinical practice guideline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f930c6e-27e7-4ef2-b112-96407f58305c">Neuroblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma:</b> Limited data available: <b>Note:</b> Although aldesleukin was used in earlier protocols, it is no longer considered as standard of care in combination with isotretinoin, dinutuximab, and sargramostim due to increased adverse effects and no additional efficacy benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35839426','lexi-content-ref-30442501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35839426','lexi-content-ref-30442501'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: 3 million units/m<sup>2</sup>/day continuous infusion over 24 hours for 4 consecutive days during week 1 and 4.5 million units/m<sup>2</sup>/day continuous infusion over 24 hours for 4 consecutive days during week 2 of cycles 2 and 4 (regimen also includes isotretinoin, dinutuximab [an anti-GD2 antibody], and sargramostim) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20879881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20879881'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> There are no pediatric-specific recommendations; the presented dosing adjustments are based on experience in adult patients. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Withhold or interrupt a dose for toxicity; do not reduce the dose.</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cardiovascular toxicity:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Atrial fibrillation, supraventricular tachycardia, or bradycardia that is persistent, recurrent, or requires treatment: Withhold dose; may resume when asymptomatic with full recovery to normal sinus rhythm.</p>
<p style="text-indent:-2em;margin-left:10em;">Systolic BP &lt;90 mm Hg (with increasing pressor requirements): Withhold dose; may resume treatment when systolic BP ≥90 mm Hg and stable or pressor requirements improve.</p>
<p style="text-indent:-2em;margin-left:10em;">Any ECG change consistent with myocardial infarction (MI), ischemia or myocarditis (with or without chest pain), or suspected cardiac ischemia: Withhold dose; may resume when asymptomatic, MI/myocarditis have been ruled out, suspicion of angina is low, or there is no evidence of ventricular hypokinesia.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>CNS toxicity:</i> Mental status change, including moderate confusion or agitation. Withhold dose; may resume when resolved completely.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dermatologic toxicity:</i> Bullous dermatitis or marked worsening of preexisting skin condition: Withhold dose; may treat with antihistamines or topical products (do not use topical steroids); may resume with resolution of all signs of bullous dermatitis.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Gastrointestinal: </i>Stool guaiac repeatedly &gt;3 to 4+: Withhold dose; may resume with negative stool guaiac.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Infection:</i> Sepsis syndrome, clinically unstable: Withhold dose; may resume when sepsis syndrome has resolved, patient is clinically stable, and infection is under treatment.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Respiratory toxicity: </i>Oxygen saturation &lt;90%: Withhold dose; may resume when &gt;90%.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Retreatment with aldesleukin is contraindicated with the following toxicities:</b> Sustained ventricular tachycardia (≥5 beats), uncontrolled or unresponsive cardiac arrhythmias, chest pain with ECG changes consistent with angina or MI, cardiac tamponade, intubation &gt;72 hours, renal failure requiring dialysis for &gt;72 hours, coma or toxic psychosis lasting &gt;48 hours, repetitive or refractory seizures, bowel ischemia/perforation, or GI bleeding requiring surgery.</p></div>
<div class="block adr drugH1Div" id="F131222"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac disorder (11%; including ECG abnormality, heart failure), edema (15%), hypotension (71%), peripheral edema (28%), supraventricular tachycardia (12%), tachycardia (23%), vasodilation (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliative dermatitis (18%), pruritus (24%), skin rash (42%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis (12%), hypocalcemia (11%), hypomagnesemia (12%), weight gain (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (11%), decreased appetite (20%), diarrhea (67%; grade 4: 2%), nausea (35%), stomatitis (22%; grade 4: &lt;1%), vomiting (50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Oliguria (63%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (29%), leukopenia (16%), thrombocytopenia (37%; grade 4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (40%), increased serum aspartate aminotransferase (23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (66% to 74%; neutralizing: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (13%, including sepsis [&lt;10%], serious infection)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (12%), asthenia (23%), chills (52%), confusion (34%), dizziness (11%), drowsiness (22%), malaise (27%), pain (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (11%), dyspnea (43%), pulmonary disease (24%, including pulmonary congestion, rales, rhonchi), respiratory system disorder (11%, including acute respiratory distress syndrome, pulmonary infiltrates, respiratory failure)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (29%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (&lt;10%), cardiac arrhythmia (10%), ventricular tachycardia (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anuria (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disseminated intravascular coagulation (&lt;10%; grade 4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Coma (&lt;10%), psychosis (&lt;10%), stupor (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea (&lt;10%), rhinitis (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (grade 4), coronary artery disease (grade 4), endocarditis (grade 4), ischemic heart disease (grade 4), pericardial effusion (grade 4), phlebitis (grade 4), premature ventricular contractions (grade 4), second-degree atrioventricular block (grade 4), shock (grade 4), supraventricular cardiac arrhythmia (grade 4), syncope (grade 4), thrombosis (grade 4)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Gangrene of skin and/or subcutaneous tissues (grade 4)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperuricemia (grade 4), respiratory acidosis (grade 4)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bloody diarrhea (grade 4), gastrointestinal hemorrhage (grade 4), hematemesis (grade 4), intestinal perforation (grade 4), pancreatitis (grade 4)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (grade 4)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (grade 4), hypothermia (grade 4), paranoid ideation (grade 4), peripheral neuropathy (grade 4), seizure (grade 4, including tonic-clonic seizure)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Mydriasis (grade 4), pupillary disease (grade 4)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (grade 4), kidney failure (grade 4), renal tubular necrosis (grade 4)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (grade 4), hemoptysis (grade 4), hyperventilation (grade 4), hypoventilation (grade 4), hypoxia (grade 4), pneumothorax (grade 4), pulmonary edema (grade 4)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bacterial endocarditis, capillary leak syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neurotoxicity</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac tamponade, cardiomyopathy, hypertension, myocarditis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous pemphigoid, cellulitis, Stevens-Johnson syndrome, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus, hyperglycemia, hyperthyroidism, hyponatremia, hypophosphatemia, hypothyroidism, thyroiditis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholecystitis, colitis, exacerbation of Crohn disease, gastritis, intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, febrile neutropenia, lymphocytopenia, neutropenia, retroperitoneal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, hepatosplenomegaly</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Tissue necrosis at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral hemorrhage, cerebral vasculitis, encephalopathy, extrapyramidal reaction, insomnia, myasthenia gravis (oculo-bulbar), neuralgia, neuritis, subarachnoid hemorrhage, subdural hematoma</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (inflammatory), myopathy, myositis, rhabdomyolysis, systemic sclerosis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Glomerulonephritis (crescentic IgA)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia</p></div>
<div class="block coi drugH1Div" id="F131236"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known history of severe hypersensitivity to aldesleukin or any component of the formulation; patients with organ allografts; patients with significant cardiac (including abnormal ejection fraction, impaired wall motion, or significant coronary artery disease), pulmonary (including those with an FEV1 ≤2 liters or &lt;75% predicted for height and age), kidney, hepatic, or CNS impairment.</p></div>
<div class="block war drugH1Div" id="F131219"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Capillary leak syndrome: Severe and life-threatening capillary leak syndrome (CLS) may occur with aldesleukin treatment and result in cardiac, pulmonary, kidney, or hepatic impairment, including fatal cases. Signs and symptoms of CLS include (but are not limited to) hypotension, dyspnea, edema, and hypoalbuminemia. CLS may begin immediately after treatment initiation. Do not administer aldesleukin to patients with significant cardiac, pulmonary, kidney, or hepatic impairment. Avoid concomitant administration of medications that may contribute to additive hypotension, kidney toxicity, or hepatic toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiopulmonary toxicity: Eosinophilic infiltration of cardiac and pulmonary tissue may occur with aldesleukin. In a scientific statement from the American Heart Association, interleukin-2 has been determined to be an agent that may either cause direct myocardial toxicity (rare) or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS toxicity: Treatment with aldesleukin may result in CNS toxicity (may be life-threatening); clinical manifestations may include altered mental status, speech difficulties, cortical blindness, limb or gait ataxia, hallucinations, agitation, obtundation, demyelinating polyneuropathy, and coma. Mental status may worsen for several days prior to recovery; permanent deficits have been reported. Radiological findings may include multiple and occasionally single cortical lesions on MRI (with evidence of demyelination). Aldesleukin may cause seizure; avoid use in patients with seizure disorder or abnormal CNS imaging. Patients should be evaluated and treated for CNS metastases prior to treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperglycemia: Hyperglycemia and/or diabetes mellitus have been reported with aldesleukin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis, have occurred with aldesleukin treatment. Treatment with aldesleukin may result in infusion reactions; signs/symptoms include fever, chills, and/or rigors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune-mediated adverse reactions: Aldesleukin has been associated with exacerbation or new onset of autoimmune disease or inflammatory disorders; may be severe or fatal. Exacerbation of Crohn disease, colitis, scleroderma, thyroiditis, inflammatory arthritis, diabetes mellitus, oculo-bulbar myasthenia gravis, crescentic IgA glomerulonephritis, cholecystitis, cerebral vasculitis, Stevens-Johnson syndrome, bullous pemphigoid, myocarditis, myositis, and neuritis (including optic neuritis leading to blindness) have been reported following treatment with aldesleukin. Thyroid disease (hypothyroidism, biphasic thyroiditis, and thyrotoxicosis) may occur with aldesleukin treatment; the onset of hypothyroidism is usually 4 to 17 weeks after treatment initiation; may be reversible upon treatment discontinuation (Hamnvik 2011). Hypothyroidism may sometimes be preceded by hyperthyroidism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Aldesleukin treatment is associated with impaired neutrophil function (reduced chemotaxis) and an increased risk of disseminated infection, including sepsis and bacterial endocarditis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney toxicity: Aldesleukin may cause serious kidney toxicity, including oliguria and kidney failure; preexisting kidney impairment and concomitant nephrotoxic agents may increase the risk of kidney toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Transplant recipients: Aldesleukin may increase the risk of allograft rejection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contrast media: An acute/atypical array of symptoms resembling aldesleukin adverse reactions (fever, chills, nausea, vomiting, rash, pruritus, diarrhea, hypotension, edema, and oliguria) were observed within 1 to 4 hours after iodinated contrast media administration, usually when given within 4 weeks after aldesleukin treatment, although symptoms have also been reported several months after aldesleukin treatment.</p></div>
<div class="block foc drugH1Div" id="F131230"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proleukin: 22,000,000 units (1 ea)</p></div>
<div class="block geq drugH1Div" id="F131215"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F3422186"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Proleukin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">22000000 unit (per each): $6,661.76</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865588"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proleukin: 22,000,000 units (1 ea)</p></div>
<div class="block adm drugH1Div" id="F131233"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Aldesleukin doses &gt;12 to 15 million units/m<sup>2</sup> are associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:4em;">Administer aldesleukin in an inpatient hospital setting with access to an intensive care facility and specialists in cardiopulmonary and intensive care medicine.</p>
<p style="text-indent:-2em;margin-left:4em;">Administer as IV infusion over 15 minutes. If diluted solution is refrigerated, allow solution to reach room temperature prior to administration. Do not administer using an in-line filter or coadminister with other medications through the same IV line.</p></div>
<div class="block admp drugH1Div" id="F52612194"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Recommendations for antiemetics use may vary: Aldesleukin doses &gt;12 to 15 million units/m<sup>2</sup> are associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637'])">Ref</a></span>). Aldesleukin is not included in the most updated pediatric classification of acute emetogenicity clinical practice guideline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral: IV: Allow solution to reach room temperature prior to administration; infuse over 15 minutes; flush line before and after with D5W, particularly if maintenance IV line contains sodium chloride. Some protocols infuse as a continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9586888','lexi-content-ref-20879881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9586888','lexi-content-ref-20879881'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F131231"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, metastatic:</b> Treatment of metastatic melanoma in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, metastatic:</b> Treatment of metastatic renal cell carcinoma in adults.</p></div>
<div class="block mst drugH1Div" id="F131296"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298698"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F131224"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Aldesleukin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Aldesleukin may increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interferons (Alfa): May enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination. Management: Consider using lower doses to minimize toxicity of this combination. Only coadminister aldesleukin and interferons (alfa) in patients in whom potential benefits outweigh the risk of severe toxicity. Monitor renal and cardiac function closely if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iodinated Contrast Agents: Aldesleukin may enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49088720"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify the patient is not pregnant prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy.</p></div>
<div class="block pri drugH1Div" id="F131239"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to aldesleukin may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Capillary leak syndrome may occur in any patient. If this occurs during pregnancy, hypotension and decreased placental perfusion may result; monitor fetus and neonate.</p></div>
<div class="block brc drugH1Div" id="F5520981"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if aldesleukin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant (including impaired immune function), breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F131228"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Baseline</i>: CBC with differential; blood chemistries, including electrolytes, kidney, and hepatic function tests; baseline cardiac ejection fraction; pulmonary function tests; thyroid function. Evaluate for baseline coronary artery disease and CNS impairment prior to treatment initiation. Verify pregnancy status in patients that could become pregnant.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Monitoring during therapy</i>: CBC with differential, blood chemistries, including electrolytes, kidney and hepatic function (daily); thyroid function (thyroid-stimulating hormone every 2 to 3 months during aldesleukin treatment [Hamnvik 2011]); assessment of capillary leak syndrome (vital signs [temperature, pulse, BP, and respiration rate], weight, fluid intake, serum albumin, urine output). Monitor for signs/symptoms of capillary leak syndrome (hypotension, dyspnea, edema, and hypoalbuminemia), cardiopulmonary toxicity; CNS toxicity (mental status changes, speech difficulty, cortical blindness, limb or gait ataxia, hallucination, agitation, obtundation, demyelinating polyneuropathy, and coma), dermatologic toxicity, GI toxicity, hyperglycemia/diabetes mellitus, hypersensitivity/infusion related reaction, and infection.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F131218"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Aldesleukin is a human recombinant interleukin-2 product which promotes proliferation, differentiation, and recruitment of T and B cells, natural killer (NK) cells, and thymocytes; causes cytolytic activity in a subset of lymphocytes and subsequent interactions between the immune system and malignant cells; can stimulate lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL) cells. </p></div>
<div class="block phk drugH1Div" id="F131235"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Primarily into plasma, lymphocytes, lungs, liver, kidney, and spleen; V<sub>d</sub>: 6.3 to 7.9 L (Whittington 1993)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Renal (metabolized to amino acids in the cells lining the proximal convoluted tubules of the kidney)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: Distribution: 14 ± 6 minutes; Elimination: 51 ± 11 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Distribution: 13 minutes; Terminal: 85 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily as metabolites); Clearance: 268 mL/minute</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038320"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Macrolin | Proleukin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Proleukin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Chiron</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19001327">
<a name="19001327"></a>Atkins MB, Hsu J, Lee S, et al. Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group. <i>J Clin Oncol</i>. 2008;26(35):5748-5754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/19001327/pubmed" id="19001327" target="_blank">19001327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10561265">
<a name="10561265"></a>Atkins MB, Lotze MT, Dutcher JP, et al. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. <i>J Clin Oncol</i>. 1999;17(7):2105-2116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/10561265/pubmed" id="10561265" target="_blank">10561265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30777131">
<a name="30777131"></a>Buchbinder EI, Dutcher JP, Daniels GA, et al. Therapy with high-dose interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.<i> J Immunother Cancer</i>. 2019;7(1):49. doi:10.1186/s40425-019-0522-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/30777131/pubmed" id="30777131" target="_blank">30777131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35839426">
<a name="35839426"></a>Desai AV, Gilman AL, Ozkaynak MF, et al. Outcomes following GD2-directed postconsolidation therapy for neuroblastoma after cessation of random assignment on ANBL0032: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2022;40(35):4107-4118. doi:10.1200/JCO.21.02478<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/35839426/pubmed" id="35839426" target="_blank">35839426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22010182">
<a name="22010182"></a>Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. <i>J Natl Cancer Inst</i>. 2011;103(21):1572-1587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/22010182/pubmed" id="22010182" target="_blank">22010182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18048825">
<a name="18048825"></a>Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. <i>J Clin Oncol</i>. 2007;25(34):5426-5434. doi:10.1200/JCO.2007.12.0253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/18048825/pubmed" id="18048825" target="_blank">18048825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18457330">
<a name="18457330"></a>Klapper JA, Downey SG, Smith FO, et al. High-Dose Interleukin-2 for the Treatment of Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Response and Survival in Patients Treated in the Surgery Branch at the National Cancer Institute Between 1986 and 2006. <i>Cancer</i>. 2008;113(2):293-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/18457330/pubmed" id="18457330" target="_blank">18457330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30442501">
<a name="30442501"></a>Ladenstein R, Pötschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. <i>Lancet Oncol</i>. 2018;19(12):1617-1629. doi:10.1016/S1470-2045(18)30578-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/30442501/pubmed" id="30442501" target="_blank">30442501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9586888">
<a name="9586888"></a>Legha SS, Ring S, Eton O, et al. Development of a Biochemotherapy Regimen With Concurrent Administration of Cisplatin, Vinblastine, Dacarbazine, Interferon Alfa, and Interleukin-2 for Patients With Metastatic Melanoma.<i>J Clin Onco</i>l. 1998;16(5):1752-1759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/9586888/pubmed" id="9586888" target="_blank">9586888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15625368">
<a name="15625368"></a>McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma [published correction appears in <i>J Clin Oncol</i>. 2005;23(12):2877]. <i>J Clin Oncol</i>. 2005;23(1):133-141. doi: 10.1200/JCO.2005.03.206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/15625368/pubmed" id="15625368" target="_blank">15625368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi:10.1002/pbc.27646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Proleukin.1">
<a name="Proleukin.1"></a>Proleukin (aldesleukin) [prescribing information]. Malvern, PA: Clinigen Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18765555">
<a name="18765555"></a>Smith FO, Downey SG, Klapper JA, et al. Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction With Vaccines. <i>Clin Cancer Res</i>. 2008;14(17):5610-5618.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/18765555/pubmed" id="18765555" target="_blank">18765555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7693434">
<a name="7693434"></a>Whittington R, Faulds D. Interleukin-2: A Review of Its Pharmacological Properties and Therapeutic Use in Patients With Cancer. <i>Drugs</i>. 1993;46(3):446-514.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/7693434/pubmed" id="7693434" target="_blank">7693434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20879881">
<a name="20879881"></a>Yu AL, Gilman AL, Ozkaynak MF, et al; Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. <i>N Engl J Med</i>. 2010;363(14):1324-1334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aldesleukin-drug-information/abstract-text/20879881/pubmed" id="20879881" target="_blank">20879881</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9413 Version 246.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
